Age- and Sex-Dependent Behavioral and Neurochemical Alterations in hLRRK2-G2019S BAC Mice

The G2019S mutation in the leucine-rich repeat kinase 2 (<i>LRRK2</i>) gene is associated with late-onset Parkinson’s disease (PD). Although PD affects men and women differently, longitudinal studies examining sex- and age-dependent alterations in mice carrying the G2019S mutation are li...

Full description

Bibliographic Details
Published in:	Biomolecules
Main Authors:	Ning Yao, Olga Skiteva, Karima Chergui
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Subjects:	BAC: bacterial artificial chromosome DA: dopaminergic DAT: dopamine transporter KI: knock-in LRRK2: leucine-rich repeat kinase 2 PD: Parkinson’s disease
Online Access:	https://www.mdpi.com/2218-273X/13/1/51

Similar Items

Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson’s Disease
by: Genta Ito, et al.
Published: (2023-05-01)

LRRK2 Inhibition Mitigates the Neuroinflammation Caused by TLR2-Specific α-Synuclein and Alleviates Neuroinflammation-Derived Dopaminergic Neuronal Loss
by: Dong-Hwan Ho, et al.
Published: (2022-03-01)

Expression of G2019S LRRK2 in Rat Primary Astrocytes Mediates Neurotoxicity and Alters the Dopamine Synthesis Pathway in N27 Cells via Astrocytic Proinflammatory Cytokines and Neurotrophic Factors
by: Dong Hwan Ho, et al.
Published: (2024-05-01)

LRRK2 kinase inhibition protects against Parkinson's disease-associated environmental toxicants
by: Neda M. Ilieva, et al.
Published: (2024-06-01)

Exploring environmental modifiers of LRRK2-associated Parkinson’s disease penetrance: An exposomics and metagenomics pilot study on household dust
by: Begoña Talavera Andújar, et al.
Published: (2024-12-01)

Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson's disease
by: Barbara Calamini, et al.
Published: (2021-06-01)

LRRK2 at Striatal Synapses: Cell-Type Specificity and Mechanistic Insights
by: Patrick D. Skelton, et al.
Published: (2022-01-01)

LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease
by: Chen Yao, et al.
Published: (2010-10-01)

Neuroprotective role of ranolazine in Parkinson disease: Drosophila melanogaster model
by: Parvesh, et al.
Published: (2025-01-01)

Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice
by: Chiara Domenicale, et al.
Published: (2022-04-01)

Regional nigral neuromelanin degeneration in asymptomatic leucine-rich repeat kinase 2 gene carrier using MRI
by: Linlin Gao, et al.
Published: (2024-05-01)

Differential LRRK2 Signalling and Gene Expression in WT-LRRK2 and G2019S-LRRK2 Mouse Microglia Treated with Zymosan and MLi2
by: Iqra Nazish, et al.
Published: (2023-12-01)

The Multifaceted Role of LRRK2 in Parkinson’s Disease
by: Dong Hwan Ho, et al.
Published: (2025-04-01)

Markov State Models and Molecular Dynamics Simulations Provide Understanding of the Nucleotide-Dependent Dimerization-Based Activation of LRRK2 ROC Domain
by: Xinyi Li, et al.
Published: (2021-09-01)

The role of autophagy in Parkinson’s disease: a gender difference overview
by: Laura Cucinotta, et al.
Published: (2024-06-01)

LRRK2 aggravates kidney injury through promoting MFN2 degradation and abnormal mitochondrial integrity
by: Shun Zhang, et al.
Published: (2023-10-01)

Affective phenotypes in heterozygous LRRK2 R1441G knock-in mice
by: Marcus H. F. Ng, et al.
Published: (2025-08-01)

LRRK2 Structure-Based Activation Mechanism and Pathogenesis
by: Xiaojuan Zhang, et al.
Published: (2023-03-01)

Is Glial Dysfunction the Key Pathogenesis of <i>LRRK2</i>-Linked Parkinson’s Disease?
by: Tatou Iseki, et al.
Published: (2023-01-01)

Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival
by: Jongkyun Kang, et al.
Published: (2024-06-01)

Neuronal Firing and Glutamatergic Synapses in the Substantia Nigra Pars Reticulata of LRRK2-G2019S Mice
by: Giacomo Sitzia, et al.
Published: (2022-11-01)

Precision medicine in Parkinson’s disease patients with LRRK2 and GBA risk variants – Let’s get even more personal
by: Christian U. von Linstow, et al.
Published: (2020-10-01)

Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity
by: Xiaodong Ding, et al.
Published: (2017-02-01)

Early⁃onset Parkinson's disease caused by LRRK2 R1067Q and GBA R202Q variation: one case report
by: LIU Chen, et al.
Published: (2024-03-01)

Role of leucine-rich repeat kinase 2 in severe acute pancreatitis
by: Yasuo Otsuka, et al.
Published: (2024-02-01)

The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases
by: George Tsafaras, et al.
Published: (2022-10-01)

(G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse
by: Jun-Shiao Chou, et al.
Published: (2014-08-01)

Short-term lipopolysaccharide treatment leads to astrocyte activation in LRRK2 G2019S knock-in mice without loss of dopaminergic neurons
by: Hoang Kieu Chi Ngo, et al.
Published: (2025-03-01)

Molecular and spatial transcriptomic classification of midbrain dopamine neurons and their alterations in a LRRK2G2019S model of Parkinson’s disease
by: Zachary Gaertner, et al.
Published: (2025-05-01)

Editorial: LRRK2—Fifteen Years From Cloning to the Clinic
by: Hardy Rideout, et al.
Published: (2022-04-01)

Enhancement of D1 dopaminergic responses in aged LRRK2 G2019S knock-in mice
by: Daniela Mercatelli, et al.
Published: (2025-05-01)

LRRK2 decreases microglial actin dynamics by filamentous actin depolymerization and Rac1 inhibition
by: Beomsue Kim, et al.
Published: (2022-11-01)

Neuroimaging Techniques in Differentiating Parkinson’s Disease from Drug-Induced Parkinsonism: A Comprehensive Review
by: Jamir Pitton Rissardo, et al.
Published: (2023-11-01)

Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk
by: Robert K. Lesniak, et al.
Published: (2022-10-01)

Early⁃onset Parkinson's disease with a novel variant in the LRRK2 and Parkin genes: one case report
by: Chun⁃xia DUAN, et al.
Published: (2019-07-01)

Double Trouble: Association of Malignant Melanoma with Sporadic and Genetic Forms of Parkinson’s Disease and Asymptomatic Carriers of Related Genes: A Brief Report
by: Christos Koros, et al.
Published: (2023-07-01)

Structural biology of the LRRK2 GTPase and Kinase domains: Implications for regulation
by: Bernd Karl Gilsbach, et al.
Published: (2014-05-01)

In vivo overexpression of synaptogyrin‐3 promotes striatal synaptic dopamine uptake in LRRK2R1441G mutant mouse model of Parkinson's disease
by: Philip Wing‐Lok Ho, et al.
Published: (2023-02-01)

CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and α-Synuclein modulation in dopaminergic neurons
by: Xiaobing Qing, et al.
Published: (2017-10-01)

Upregulation of LRRK2 following traumatic brain injury does not directly phosphorylate Thr175 tau
by: Neil Donison, et al.
Published: (2023-11-01)